Adolescence can be a confusing time, and this is doubly true for teenagers with type 1 diabetes. At a stage when everyone is starting to figure out who they are, the teenager with type 1 must also decide how much they want diabetes to be a part of their identity. Katie Bacon, the mother of a teenager with type 1, spoke with a range of experts and peers who shared their expertise and experiences on this subject. Continue Reading »
The American Diabetes Association's 81st Scientific Sessions brought together great minds in diabetes for exciting news and discussions. Check out highlights from the largest conference in diabetes, including automated insulin delivery, continuous glucose monitoring, extremely promising drugs in development, and more. Continue Reading »
David Kendall and Danilo Verge of Zealand Pharma spoke with diaTribe about Zegalogue (dasiglucagon), a new emergency glucagon injection used to treat severe hypoglycemia in people with diabetes over the age of six. Read their insights on this life-saving treatment. Continue Reading »
The American Diabetes Association’s 81st Scientific Sessions is going strong. Updates from days two and three include promising Omnipod 5 results, Medtronic’s seven-day infusion set, and Control-IQ real-world data. Continue Reading »
We bring you the most exciting news from day one of the 81st ADA Scientific sessions, including updates on inhaled insulin, digital diabetes management programs, automated insulin delivery, beta cell replacement therapies, and more. Continue Reading »
A remote six-month clinical trial is recruiting 150 children between the ages of two to five whose families are interested in trying automated insulin delivery. The study will evaluate the use of automated insulin delivery in young children to see if it improves Time in Range and other health metrics. Continue Reading »
The latest innovations in diabetes technology have brought Time in Range (TIR) to the forefront of diabetes care. Read to learn about the most exciting TIR news from one of the biggest international diabetes conferences of the year, with a special focus on automated insulin delivery systems for kids, adults, and seniors. Continue Reading »
Provention Bio’s new injectable drug was recommended by an FDA committee for approval on May 25, 2021. Studies show that Teplizumab can delay, for people at risk for type 1, the onset of the condition for two years or more. Learn what happened at the FDA meeting and what might come next. Continue Reading »
